Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $10

Benzinga · 3d ago
Guggenheim analyst Paul Jeng maintains Coherus Oncology (NASDAQ:CHRS) with a Buy and lowers the price target from $12 to $10.